“…IncobotulinumtoxinA has demonstrated efficacy and safety in the treatment of subjects with CD in two Phase III clinical trials 8–10. Additionally, the long-term safety and effectiveness of incobotulinumtoxinA in the treatment of CD have been established in one repeated dose trial 11,12…”